Key regions: Australia, Brazil, United Kingdom, Europe, Canada
Suriname, a small country in South America, has seen a significant development in the Other Vaccines market. This market includes vaccines for diseases other than COVID-19, such as influenza, hepatitis, and human papillomavirus (HPV).
Customer preferences: In Suriname, there is a growing awareness of the importance of preventive healthcare, which has led to an increase in demand for vaccines. Additionally, the government has implemented various vaccination programs to improve the overall health of the population.
Trends in the market: One of the main trends in the Other Vaccines market in Suriname is the increasing demand for HPV vaccines. This is due to the rising incidence of cervical cancer in the country, which is caused by the HPV virus. As a result, the government has launched a national HPV vaccination program for young girls. Another trend is the growing popularity of combination vaccines, which offer protection against multiple diseases in a single shot.
Local special circumstances: Suriname has a relatively small population, which means that the market for vaccines is also small. However, the government's commitment to improving healthcare has created opportunities for vaccine manufacturers to enter the market. Additionally, the country's tropical climate makes it a suitable environment for the spread of certain diseases, which has increased the demand for vaccines.
Underlying macroeconomic factors: Suriname is a lower-middle-income country with a developing economy. The country's healthcare system is still in the process of being modernized, which has created opportunities for investment in the healthcare sector. However, the country's economy has been negatively impacted by the COVID-19 pandemic, which has led to a decrease in government spending on healthcare. This could potentially slow down the growth of the Other Vaccines market in the short term.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
